Abstract
Background and Aims: We investigated the relative etiological role of prior hepatitis B virus (HBV) infection and nonalcoholic fatty liver disease (NAFLD) in the development of non-B non-C, non-alcohol or specific cause-related hepatocellular carcinoma (NBNC-NA-NS HCC) in an HBV-endemic area of Korea. Methods: A total of 329 patients with NBNC-NA-NS HCC were enrolled in this study. Prior HBV infection was defined as the presence of isolated IgG hepatitis B core antibody (anti-HBc), and NAFLD was diagnosed by the findings from the imaging in the absence of a history of excessive alcohol consumption. Results: Prior HBV infection was the most common cause of underlying liver disease (76.6%). Only 8.2% of the patients had NAFLD as the only risk factor and the same proportion of patients had evidence of both prior HBV infection and NAFLD. Patients without definitive causes accounted for 7.0% of the cases. During the past 10 years, the relative proportion of isolated IgG anti-HBc-positive HCC decreased significantly from 86.6% in 2001–2005 to 67.4% in 2006–2010 (p < 0.0001) and that of NAFLD-related HCC increased from 3.8% to 12.2% in the same period, respectively (p = 0.008). The mean age of NAFLD-related HCC patients (67.3 years) was significantly older than that of HCC patients related to prior HBV infection (61.2 years, p < 0.001). Conclusions: NAFLD-related HCC increased significantly while HCC related to prior HBV infection decreased during the past 10 years in an HBV-endemic area of Korea; however, the relative etiological role of prior HBV infection was still greater than that of NAFLD in the development of NBNC-NA-NS HCC.
Journal Section:
Paper
References
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011.
2.
Yang JD, Roberts LR: Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010;7:448–458.
[PubMed]
3.
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB: Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005;54:533–539.
[PubMed]
4.
Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y: Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol 2008;43:967–974.
[PubMed]
5.
Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M: Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134–140.
[PubMed]
6.
Harrison SA, Torgerson S, Hayashi PH: The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003;98:2042–2047.
[PubMed]
7.
Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349–1354.
[PubMed]
8.
Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K: Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009;44(suppl 19):89–95.
[PubMed]
9.
Matsuzaki Y, Sato M, Saito Y, Karube M, Doy M, Shoda J, Abei M, Tanaka N, Hadama T, Kinoshita M: The role of previous infection of hepatitis B virus in Hbs antigen negative and anti-HCV negative Japanese patients with hepatocellular carcinoma: etiological and molecular biological study. J Exp Clin Cancer Res 1999;18:379–389.
[PubMed]
10.
Tamori A, Nishiguchi S, Kubo S, Narimatsu T, Habu D, Takeda T, Hirohashi K, Shiomi S: HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J Med Virol 2003;71:492–498.
[PubMed]
11.
Berasain C, Betes M, Panizo A, Ruiz J, Herrero JI, Civeira MP, Prieto J: Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 2000;47:429–435.
[PubMed]
12.
Chan HL, Tsang SW, Leung NW, Tse CH, Hui Y, Tam JS, Chan FK, Sung JJ: Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol 2002;97:1211–1215.
[PubMed]
13.
Fukuda R, Ishimura N, Kushiyama Y, Moriyama N, Ishihara S, Chowdhury A, Tokuda A, Sakai S, Akagi S, Watanabe M, Fukumoto S: Hepatitis B virus with X gene mutation is associated with the majority of serologically ‘silent’ non-B, non-C chronic hepatitis. Microbiol Immunol 1996;40:481–488.
[PubMed]
14.
Korean Liver Cancer Study Group and National Cancer Center: Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009;15:391–423.
[PubMed]
15.
Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB: Fatty liver: imaging patterns and pitfalls. Radiographics 2006;26:1637–1653.
[PubMed]
16.
Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, Dhotre KB, Murphy RC, Van Ness GR, Stabach N, Robert ME, Bower WA, Bialek SR, Sofair AN: The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol 2008;103:2727–2736, quiz 2737.
[PubMed]
17.
Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M: Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2010;45:86–94.
[PubMed]
18.
Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM: Obesity and hepatocellular carcinoma. Gastroenterology 2004;127:S97–S103.
[PubMed]
19.
Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ: Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008;135:111–121.
[PubMed]
20.
Sanchez-Quijano A, Jauregui JI, Leal M, Pineda JA, Castilla A, Abad MA, Civeira MP, Garcia de Pesquera F, Prieto J, Lissen E: Hepatitis B virus occult infection in subjects with persistent isolated anti-HBC reactivity. J Hepatol 1993;17:288–293.
[PubMed]
21.
Chemin I, Zoulim F, Merle P, Arkhis A, Chevallier M, Kay A, Cova L, Chevallier P, Mandrand B, Trepo C: High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 2001;34:447–454.
[PubMed]
22.
Shim J, Kim BH, Kim NH, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R: Clinical features of HBsAg-negative but anti-HBC-positive hepatocellular carcinoma in a hepatitis B virus endemic area. J Gastroenterol Hepatol 2005;20:746–751.
[PubMed]
23.
Fang Y, Shang QL, Liu JY, Li D, Xu WZ, Teng X, Zhao HW, Fu LJ, Zhang FM, Gu HX: Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect 2009;58:383–388.
[PubMed]
24.
Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD: Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol 2007;22:778–787.
[PubMed]
25.
Oh KC, Park SH, Park JC, Jin DK, Park CS, Kim KO, Jang HJ, Lee JY, Park CH, Han TH, Yoo KS, Kim JH, Kim DJ, Lee MS, Park CK: Is the prevalence of cryptogenic hepatocellular carcinoma increasing in Korea? (in Korean). Korean J Gastroenterol 2005;45:45–51.
[PubMed]
26.
Park NH, Chung YH, Lee HS: Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology 2010;53:20–28.
[PubMed]
27.
Bugianesi E: Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007;11:191–207, x–xi.
[PubMed]
28.
Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820–1832.
[PubMed]
29.
Kusakabe A, Tanaka Y, Orito E, Sugauchi F, Kurbanov F, Sakamoto T, Shinkai N, Hirashima N, Hasegawa I, Ohno T, Ueda R, Mizokami M: A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol 2007;42:298–305.
[PubMed]
30.
Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxi A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trepo C, Villa E, Will H, Zanetti AR, Zoulim F: Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652–657.
[PubMed]
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.
